Although tumor necrosis factor-alpha (TNF-α) inhibitors remain the most widely prescribed biologics for rheumatoid arthritis (RA) patients refractory to conventional DMARD treatment (the first-line standard of care), the RA drug market boasts a variety of targeted agents from many drug classes, all largely competing for shares of the TNF-refractory population. The continued launch of biosimilars across the major markets will make the crowded therapy market more competitive. Increasing safety concerns about the JAK inhibitor class have pushed use of these agents to follow use of TNF-α inhibitors, primarily impacting the uptake of Xeljanz in the G7 markets. Although the late-phase pipeline is relatively sparse, the sheer number of biologics and targeted oral therapies available for RA ensures that marketers face fierce competition and increasing challenges to gain and maintain market share.
Markets covered: United States, EU5, Japan
Primary research: 24 country-specific interviews with thought-leading rheumatologists
Epidemiology: Number of total, diagnosed, and drug-treated prevalent cases of RA by country; number of diagnosed prevalent cases of RA by severity
Emerging therapies: Phase 3/PR: 1 drug; Phase 2: 7 drugs; coverage of select early-phase products
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.